Ensysce Biosciences (ENSC, Financial) has successfully completed Part 1 of its second clinical trial aimed at evaluating PF614-MPAR's effectiveness in overdose protection. This study showcased that the integration of Ensysce's TAAPTM and MPAR technologies can offer substantial pain relief while safeguarding against the dangers of overdose, whether accidental or intentional.
The initial phase results demonstrated that a 100 mg dosage of PF614-MPAR efficiently delivers oxycodone for severe pain management while limiting overdose risk when higher-than-prescribed amounts are consumed. Participants served as their own control, receiving up to five 100 mg doses of the PF614-MPAR with overdose protection compared to the standard PF614.
Data showed that taking three or more doses of PF614-MPAR at once resulted in a reduced maximum release of oxycodone compared to the same number of doses of PF614 alone. Increasing the dose to five units of PF614-MPAR demonstrated even more significant overdose protection.
Furthermore, the trial's safety data reported no unexpected adverse events for either PF614 or PF614-MPAR, underscoring the treatment's safety profile. The study will now advance to Parts 2 and 3, which will explore the drug's potential food interactions and the effects of repeated dosing respectively. The cumulative findings will guide the final development of the drug product, paving the way for its eventual commercialization.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Ensysce Biosciences Inc (ENSC, Financial) is $46.73 with a high estimate of $75.00 and a low estimate of $18.45. The average target implies an upside of 2,283.93% from the current price of $1.96. More detailed estimate data can be found on the Ensysce Biosciences Inc (ENSC) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Ensysce Biosciences Inc's (ENSC, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
